Trials / Completed
CompletedNCT03508011
A Study of IMP4297 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Impact Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. Patients with advanced breast cancer, ovarian cancer or prostate cancer are preferred. There are two stages to this study: a dose-escalation stage and a dose-expansion stage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMP4297 | The dose levels will be escalated following a modified 3+3 dose escalation scheme. |
Timeline
- Start date
- 2017-08-23
- Primary completion
- 2020-12-16
- Completion
- 2020-12-16
- First posted
- 2018-04-25
- Last updated
- 2021-03-30
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03508011. Inclusion in this directory is not an endorsement.